GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
FDC Ltd

FDC Ltd Reports Q2 FY27 Consolidated Revenue of Rs. 572 crores, up 21.0% YoY

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 27 Oct 2026, 07:22 PM IST  ·  BSE ID: 43d44b3f-8508-4ea5-a5ed-01cd90b0bf5b
View Original BSE Filing (PDF)
💡
In Simple Terms
FDC Ltd reported higher sales and profits for the September quarter, driven by strong growth in its domestic and international medicine businesses.
🤖 AI Summary
  • FDC Ltd reported unaudited consolidated revenue from operations of Rs. 572 crores for Q2 FY27, up 21.0% Y-o-Y.
  • Domestic Formulations revenue grew 22.6% Y-o-Y to Rs. 467 crores, led by Electral, Enerzal, and Zifi brands.
  • International Formulations revenue increased 28.5% Y-o-Y in Q2 FY27 and 47.6% in H1 FY27.
  • EBITDA for Q2 FY27 stood at Rs. 64 crores, with an EBITDA margin of 11.2% compared to 7.1% in Q2 FY26.
  • Profit After Tax (PAT) for Q2 FY27 was Rs. 49 crores, reflecting a 72.9% Y-o-Y increase.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
Rs. 572 crores
21.0%
EBITDA (Q2 FY27)
Rs. 64 crores
90.2%
EBITDA Margin (Q2 FY27)
11.2%
PAT (Q2 FY27)
Rs. 49 crores
72.9%
Domestic Formulations (Q2 FY27)
Rs. 467 crores
22.6%
International Formulations (Q2 FY27)
Rs. 75 crores
28.5%
APIs (Q2 FY27)
Rs. 28 crores
-4.8%
🏢 How This Affects the Company
📈
Business Impact
The company's Domestic Formulations segment returned to double-digit growth, improving its position in the Indian Pharmaceutical Market, while International Formulations sustained its growth momentum.
💰
Financial Impact
Consolidated revenue from operations increased to Rs. 572 crores for Q2 FY27. EBITDA margin expanded to 11.2% in Q2 FY27 from 7.1% in Q2 FY26, contributing to higher Profit Before Tax and Profit After Tax.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results press release.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, as Q2 FY27 EPS rose to Rs. 3.01 from Rs. 1.75 in Q2 FY26.
🔍
Management Signal
Management's focus on domestic and international formulations is evident, with stated efforts to recover key brands like Zifi.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 results — monitor sustained growth in Domestic and International Formulations.
Updates on API segment performance — check for recovery in key molecule sales.
IQVIA market share data — observe FDC's position among top pharmaceutical companies.
LOW RISK The filing indicates positive financial and operational performance, with no immediate risks flagged.
💡 Investor Takeaway
FDC Ltd's Q2 FY27 consolidated revenue from operations increased 21.0% Y-o-Y to Rs. 572 crores. Profit After Tax rose 72.9% Y-o-Y to Rs. 49 crores, with the EBITDA margin improving to 11.2% from 7.1% in Q2 FY26, driven by domestic and international formulation growth.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 consolidated revenue from operations increased by 21.0% Y-o-Y to Rs. 572 crores, indicating strong top-line growth.
  • EBITDA margin improved significantly to 11.2% in Q2 FY27 from 7.1% in Q2 FY26, demonstrating enhanced operational efficiency.

⚠️ Concerns

  • API business revenue declined by 4.8% Y-o-Y in Q2 FY27 to Rs. 28 crores and 4.0% Y-o-Y in H1 FY27 to Rs. 52 crores.
  • International Formulations (Non-US) segment showed slower growth of 1.6% Y-o-Y in Q2 FY27, reaching Rs. 45 crores.
📅 Company Track Record
In Q1 FY27, FDC Ltd reported consolidated PAT up 9.2% to Rs. 132 crores, with US business revenue surging 118.4%. The company's board also approved a ₹120 Crore share buyback at ₹500 per share in October 2026, alongside the Q2 results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was FDC Ltd's consolidated revenue from operations in Q2 FY27?
FDC Ltd reported consolidated revenue from operations of Rs. 572 crores for Q2 FY27, which is a 21.0% Y-o-Y increase from Rs. 473 crores in Q2 FY26.
What was FDC Ltd's Profit After Tax (PAT) in Q2 FY27?
Profit After Tax for FDC Ltd in Q2 FY27 stood at Rs. 49 crores, representing a 72.9% Y-o-Y increase compared to Rs. 28 crores in Q2 FY26.
How did FDC Ltd's Domestic Formulations segment perform in Q2 FY27?
Domestic Formulations revenue for FDC Ltd in Q2 FY27 was Rs. 467 crores, showing a 22.6% Y-o-Y growth from Rs. 381 crores in Q2 FY26.
What was FDC Ltd's EBITDA margin in Q2 FY27?
FDC Ltd's EBITDA margin in Q2 FY27 was 11.2%, an increase from 7.1% reported in Q2 FY26.
What was the growth rate for FDC Ltd's International Formulations in Q2 FY27?
International Formulations sales for FDC Ltd grew by 28.5% Y-o-Y in Q2 FY27, reaching Rs. 75 crores from Rs. 58 crores in Q2 FY26.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.